{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T21:33:08Z","timestamp":1788039188045,"version":"build-2784847793"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Risdiplam has been shown to be safe, well tolerated, and improves or stabilizes motor function in individuals with SMA, but limited published data exists for adults. The aim of this study was to assess the efficacy, safety, and tolerability of risdiplam treatment for adults with SMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective chart review on adult patients with 5q-SMA who received risdiplam for a minimum of 6\u202fmonths, including both treatment na\u00efve and those who switched from nusinersen. Baseline demographic data was collected and outcomes included the Revised Upper Limb Module, Children\u2019s Hospital of Philadelphia Adult Test of Neuromuscular Disorders (CHOP-ATEND), six-minute walk test, Hammersmith Functional Motor Scale-Expanded, and forced vital capacity. Assessments were performed at baseline, 6, 12, and 24\u202fmonths. Self-reported adverse effects were recorded. Linear mixed models were used for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighteen patients (mean age 41.11\u202fyears) met inclusion criteria. CHOP-ATEND scores increased at 12 (+1.99,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.030) and 24\u202fmonths (+2.12;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.042), while all other outcomes showed stability. The most common self-reported adverse effects were gastrointestinal issues. Serious adverse events included pneumonia, appendicitis, and femur and tibia\/fibula fractures. The latter two were considered unlikely related to treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Risdiplam is overall safe and well-tolerated up to 24\u202fmonths in adults with SMA. The treatment resulted in improvement or stabilization of motor and respiratory function in non-ambulatory and ambulatory patients. Improvement on the CHOP-ATEND suggests it may be a sensitive marker of change. Longer-term follow-up is needed to understand the impact of risdiplam in adults with SMA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1694037","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:34:26Z","timestamp":1768372466000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessment of safety and efficacy of risdiplam treatment in adults with spinal muscular atrophy"],"prefix":"10.3389","volume":"16","author":[{"given":"Andrea","family":"Jaworek","sequence":"first","affiliation":[{"name":"Division of Neuromuscular Disorders, Department of Neurology, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Jira","sequence":"additional","affiliation":[{"name":"Division of Neuromuscular Disorders, Department of Neurology, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Allen","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute","place":["Ottawa, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songzhu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics and Center for Biostatistics, The Ohio State University","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Kelly","sequence":"additional","affiliation":[{"name":"NextGen Precision Health, University of Missouri","place":["Columbia, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Moravec","sequence":"additional","affiliation":[{"name":"Department of Neurology, Knox Community Hospital","place":["Mount Vernon, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tellez","sequence":"additional","affiliation":[{"name":"Division of Neuromuscular Disorders, Department of Neurology, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Heintzman","sequence":"additional","affiliation":[{"name":"Division of Neuromuscular Disorders, Department of Neurology, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerold","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Neuromuscular Disorders, Department of Neurology, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Sterling","sequence":"additional","affiliation":[{"name":"Division of Neuromuscular Disorders, Department of Neurology, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kolb","sequence":"additional","affiliation":[{"name":"Division of Neuromuscular Disorders, Department of Neurology, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William David","family":"Arnold","sequence":"additional","affiliation":[{"name":"NextGen Precision Health, University of Missouri","place":["Columbia, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakri","family":"Elsheikh","sequence":"additional","affiliation":[{"name":"Division of Neuromuscular Disorders, Department of Neurology, College of Medicine, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/genes14071377","article-title":"Spinal muscular atrophy treatment in patients identified by newborn screening\u2014a systematic review","volume":"14","author":"Aragon-Gawinska","year":"2023","journal-title":"Genes"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next","volume":"21","author":"Wirth","year":"2020","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ncl.2020.03.002","article-title":"Spinal muscular atrophy in the treatment era","volume":"38","author":"Waldrop","year":"2020","journal-title":"Neurol Clin"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D\u2019Amico","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41434-022-00349-y","article-title":"Curing SMA: are we there yet?","volume":"30","author":"Reilly","year":"2023","journal-title":"Gene Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Schreiber-Katz","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fneur.2021.650532","article-title":"Safety, tolerability, and effect of Nusinersen in non-ambulatory adults with spinal muscular atrophy","volume":"12","author":"Elsheikh","year":"2021","journal-title":"Front Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fneur.2021.650535","article-title":"Safety, tolerability, and effect of Nusinersen treatment in ambulatory adults with 5q-SMA","volume":"12","author":"Elsheikh","year":"2021","journal-title":"Front Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"E317","DOI":"10.1212\/CPJ.0000000000001033","article-title":"Nusinersen treatment in adults with spinal muscular atrophy","volume":"11","author":"Duong","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/ene.15501","article-title":"Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts\u2019 study","volume":"29","author":"V\u00e1zquez-Costa","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s40120-024-00653-2","article-title":"Effectiveness of nusinersen in adolescents and adults with spinal muscular atrophy: systematic review and meta-analysis","volume":"13","author":"Hagenacker","year":"2024","journal-title":"Neurol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.braindev.2022.10.006","article-title":"Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2","volume":"45","author":"Iwayama","year":"2023","journal-title":"Brain Dev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"6004","DOI":"10.1007\/s00415-024-12567-y","article-title":"Long-term impact of nusinersen on motor and electrophysiological outcomes in adolescent and adult spinal muscular atrophy: insights from a multicenter retrospective study","volume":"271","author":"Wang","year":"2024","journal-title":"J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","article-title":"Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","volume":"270","author":"Oskoui","year":"2023","journal-title":"J Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mus.27804","article-title":"Risdiplam in non-sitter patients aged 16 years and older with 5q spinal muscular atrophy","volume":"67","author":"\u00d1ungo Garz\u00f3n","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e16099","DOI":"10.1111\/ene.16099","article-title":"Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: a systematic comparison of electrophysiologic with clinical outcome measures","volume":"31","author":"Kessler","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12883-024-03562-x","article-title":"Risdiplam therapy in adults with 5q-SMA: observational study on motor function and treatment satisfaction","volume":"24","author":"Bjelica","year":"2024","journal-title":"BMC Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s00415-024-12203-9","article-title":"Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment","volume":"271","author":"Brakemeier","year":"2024","journal-title":"J Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JND-230197","article-title":"Risdiplam real world data - looking beyond motor neurons and motor function measures","volume":"11","author":"Sitas","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/mus.28327","article-title":"Risdiplam in adult patients with 5q spinal muscular atrophy: a single-center longitudinal study","volume":"71","author":"Gavriilaki","year":"2024","journal-title":"Muscle Nerve"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1007\/s00415-024-12318-z","article-title":"JEWELFISH: 24-month results from an open-label study in non-treatment-na\u00efve patients with SMA receiving treatment with risdiplam","volume":"271","author":"Chiriboga","year":"2024","journal-title":"J Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mus.25120","article-title":"Six-minute walk test is reliable and valid in spinal muscular atrophy","volume":"54","author":"Dunaway Young","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1177\/0883073811420294","article-title":"Validation of the expanded Hammersmith functional motor scale in spinal muscular atrophy type II and III","volume":"26","author":"Glanzman","year":"2011","journal-title":"J Child Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","article-title":"Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134","volume":"25","author":"Wadman","year":"2018","journal-title":"Eur J Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nmd.2021.10.009","article-title":"Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes","volume":"32","author":"Coratti","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13023-020-01367-y","article-title":"Natural history of lung function in spinal muscular atrophy","volume":"15","author":"Wijngaarde","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"100862","DOI":"10.1016\/j.lanepe.2024.100862","article-title":"Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study","volume":"39","author":"G\u00fcnther","year":"2024","journal-title":"Lancet Regional Health"},{"key":"ref35","year":"2024"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00402-010-1096-1","article-title":"Fractures in proximal spinal muscular atrophy","volume":"130","author":"Fujak","year":"2010","journal-title":"Arch Orthop Trauma Surg"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/165019701750300609","article-title":"Fracture risk in patients with muscular dystrophy and spinal muscular atrophy","volume":"33","author":"Vestergaard","year":"2001","journal-title":"J Rehabil Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.nmd.2017.01.019","article-title":"Low bone mineral density and fractures are highly prevalent in pediatric patients with spinal muscular atrophy regardless of disease severity","volume":"27","author":"Wasserman","year":"2017","journal-title":"Neuromuscul Disord"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1694037\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:54:08Z","timestamp":1771916048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1694037\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":38,"alternative-id":["10.3389\/fneur.2025.1694037"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1694037","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1694037"}}